GlobeNewswire

HSBC FRANCE: Pre Stabilisation Notice

Share

PARIS, May 10, 2019 (GLOBE NEWSWIRE) --

HSBC FRANCE

Pre Stabilisation Notice

HSBC (contact: 'synd manager'; telephone: +44 207 992 8066) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities

The securities:
Issuer: HSBC FRANCE
Guarantor (if any): na
Aggregate nominal amount: EUR Benchmark
Description: Fixed due 17th May 2024
Offer price: tbc
Other offer terms:  
Stabilisation:
Stabilising Manager(s): HSBC France
Stabilisation period expected to start on: 10th May 2019
Stabilisation period expected to end no later than: 17th Jun 2019
Existence, maximum size & conditions of use of over-allotment facility[1]: 5% of the aggregate nominal amount
Stabilisation Venue(s) Over the counter (OTC)

In connection with the offer of the above securities, the Stabilisation Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time. Any stabilisation action or over-allotment shall be conducted in accordance with all applicable laws and rules.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC, as amended (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

[1] Please note that the existence and the maximum size of any greenshoe option, the exercise period of the greenshoe option and any conditions for exercise of the greenshoe option must also be disclosed, if such option exists. In addition, the exercise of the greenshoe option must be disclosed to the public promptly, together with all appropriate details, including in particular the date of exercise and the number and nature of securities involved 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Oboya får en viktig order i USA20.8.2019 09:31:00 CESTPressemelding

Oboya Horticulture Industries AB (publ) (”Oboya”) har genom sitt helägda dotterbolag Oboya Metal Qingdao Co. Ltd i Qingdao, Kina fått en order från befintlig kund i USA. Ordervärdet uppgår till ca 0,37 MUSD, motsvarande ca 3,59 MSEK. Ordern avser leverans av blomstervagnar och kommer att levereras från september och fram till oktober 2019. Ordervärdet uppgår till 0,37 MUSD, motsvarande ca 3,59 MSEK. Den befintliga kunden är ett av de ledande logistik-, transport- och serviceföretagen inom odlingsindustrin i Nordamerika. Blomstervagnarna kommer att användas för såväl effektiv transport som för exponering av växter eller blommor i butik. "Det är glädjande att det finns fortsatt efterfrågan på Oboyas produkter i USA, trots nuvarande handelskonflikt mellan Kina och USA. Vi kommer att fortsätta att etablera oss på marknaden och därigenom successivt öka våra marknadsandelar globalt på sikt”, säger Robert Wu, VD för Oboya Horticulture Industries AB. Erik Penser Bank AB är Oboyas Certified Adv

Oboya receives an important order in USA20.8.2019 09:31:00 CESTPress release

Oboya Horticulture Industries AB (publ) ("Oboya") has through its wholly owned subsidiary Oboya Metal Qingdao Co. Ltd. in Qingdao, China received an order from an existing customer in the United States. The order value amounted to approximately USD 0.37 million, corresponding to approximately SEK 3.59 million. The order concerns delivery of flower trolleys and will be delivered from September until October 2019. The order value amounts to USD 0.37 million, corresponding to approximately SEK 3.59 million. The existing customer is one of the leading logistics, transport and service companies in the cultivation industry in North America. The flower trolleys will be used for efficient transport as well as for the exposure of plants or flowers in stores. "It is gratifying that there is continued demand for Oboya's products in the US, despite the current trade conflict between China and the US. We will continue to establish ourselves in the market and thereby gradually increase our market sh

Conditions for sale of Riksbank certificates20.8.2019 09:30:00 CESTPress release

AUCTION DATE: AUG 20, 2019 START DATE: AUG 21, 2019 MATURITY DATE: AUG 28, 2019 NOMINAL AMOUNT: 414.0 BLN FIXED RATE: -0.25 % ALL MONETARY POLICY COUNTERPARTIES ARE INVITED TO SUBMIT BIDS TO THE RIKSBANK (08-6966970) BY 10.00 AM ON AUG 20, 2019, AT THE LATEST. CONFIRMATION OF BIDS TO E-MAIL: RBCERT@riksbank.se THE LOWEST ACCEPTED BID VOLUME IS SEK 1 MLN. THE HIGHEST ACCEPTED BID VOLUME IS SEK 414.0 BLN. RESULT OF AUCTION WILL BE PUBLISHED AT 10.15 (CET/CEST) ON AUG 20, 2019. COMPLETE TERMS AND CONDITIONS CAN BE RETRIEVED AT WWW.RIKSBANK.SE

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPressemelding

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPress release

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Nexstim reports good initial results on the use of Smartfocus® technology in treatment of major depressive disorder20.8.2019 09:00:00 CESTPress release

Press Release, Helsinki, 20 August 2019 at 10.00 am (EET) Nexstim reports good initial results on the use of Smartfocus ® technology in treatment of major depressive disorder Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD) – announces that the first white paper about the initial experiences of its NBT® system with SmartFocus® technology in treatment of MDD has been published. The white paper is published by Island Psychiatry PC, a New York -based TMS therapy provider and Nexstim. It reports the experiences in the first 10 consecutive patients completing treatment of MDD with Nexstim NBT® system at Island Psychiatry’s clinic. The treatment outcomes of these 10 adult patients were good. 50 % of the patients were in remission at the end of the treatment while 70 % had obtained a clinical response rate. These patient-reported outcomes are hi